Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double blind placebo controlled pilot trial of memantine for cognitive impairment in multiple sclerosis.

Trial Profile

Double blind placebo controlled pilot trial of memantine for cognitive impairment in multiple sclerosis.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Memantine (Primary)
  • Indications Cognition disorders; Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 01 Jun 2010 Results have been published in Multiple Sclerosis.
    • 02 May 2009 Primary endpoint results presented at the 61st Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top